Table 22:

Recommendation for daprodustat as an alternative to ESA for anemia in DD-CKD patients

Weak recommendation	This recommendation is evidence informed. The drug is currently not licensed in India, and any additional evidence with concerns on safety or effectiveness which might be available to regulators has not been appraised.
The GDG suggests that when available, daprodustat might be considered as an alternative to ESAs for correcting and maintaining hemoglobin level in DD patients with chronic kidney disease. Patients should be iron replete before the initiation of therapy.

DD: Dialysis-Dependent, CKD: Chronic kidney disease, ESA: Eythropoiesis-stimulating agents, GDG: Guideline development group